SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors.

Fiche publication

Date publication

novembre 2024

Journal

Therapeutic advances in medical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi

Tous les auteurs :
Hammel P, Smith D, Afchain P, Dominguez-Tinajero S, Seitz JF, Lievre A, Van Cutsem E, Assenat E, Di Fiore F, Peeters M, Sobhani I, Raymond E, Charton E, Vernerey D, De Mestier L, Lombard-Bohas C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39563716

Résumé

Sunitinib, a multitarget tyrosine kinase inhibitor, showed encouraging antitumor activity and manageable toxicity in patients with advanced midgut neuroendocrine tumors (NETs) in earlier results from phase I and II trials.